Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study.

Abstract

BACKGROUND:

Patients presenting with upper motor neuron (UMN) signs may widely diverge in prognosis, ranging from amyotrophic lateral sclerosis (ALS) to primary lateral sclerosis (PLS) and hereditary spastic paraplegia (hSP). Neurofilaments are emerging as potential diagnostic and prognostic biomarkers for ALS, but the diagnosis of UMN syndromes still relies mostly on clinical long-term observation and on familiarity or genetic confirmation.

OBJECTIVES:

To test whether phosphorylated neurofilament heavy chain (pNfH) may discriminate different UMN syndromes at diagnosis and to test their prognostic role among these diseases.

METHODS:

We measured the cerebrospinal fluid (CSF) and serum pNfH of 30 patients presenting with UMN signs and diagnosed with ALS, hSP, and PLS, plus 9 healthy controls (HC).

RESULTS:

ALS patients had higher levels of pNfH in CSF and serum compared to HC (p < 0.001 and p < 0.001 in CSF and serum, respectively) and PLS (p = 0.015 and p = 0.038) and hSP (p = 0.003 and p = 0.001) patients. PLS and hSP patients had similar CSF and serum pNfH concentrations, but a higher CSF pNfH concentration, compared to HC (p = 0.002 and p = 0.003 for PLS and hSP, respectively). Receiver operating characteristic curves for discriminating ALS from PLS and hSP showed an area under the curve of 0.79 for CSF and 0.81 for serum. In multivariable survival analysis including relevant clinical factors CSF pNfH represented the strongest variable predicting survival (HR 40.43; 95% CI 3.49-467.79, p = 0.003) independently of clinical group.

CONCLUSIONS:

Despite some statistical instability of the results due to limitations in sample size, our study supports the role of CSF pNfH as a prognostic biomarker for motor neuron diseases presenting with UMN signs. A potential power to discriminate between ALS and other UMN syndromes at presentation, and between all of the examined MND and HC, has been detected for both CSF and serum pNfH.

• Authors: Elisabetta Zucchi, Roberta Bedin, Antonio Fasano, Nicola Fini, Annalisa Gessani, Marco Vinceti, Jessica Mandrioli
• Journal: Neuro-degenerative diseases (Neurodegener Dis) Vol. 18 Issue 5-6 Pg. 255-261 ( 2018) ISSN: 1660-2862 [Electronic] Switzerland
• PMID: 30428468 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 S. Karger AG, Basel.

Chemical References

• Biomarkers
• Neurofilament Proteins

Topics

• Adult
• Aged
• Amyotrophic Lateral Sclerosis (cerebrospinal fluid, diagnosis)
• Biomarkers (cerebrospinal fluid)
• Disease Progression
• Female
• Humans
• Intermediate Filaments (metabolism)
• Male
• Middle Aged
• Motor Neuron Disease (cerebrospinal fluid, diagnosis)
• Motor Neurons (metabolism)
• Neurofilament Proteins (cerebrospinal fluid)
• Pilot Projects